Author

P. S. Keim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:phylogenetics / evolution· 1 Approach:statistical model· 1

Frequent Co-Authors

E. W. Settles· 3 shared S. A. Jaramillo· 3 shared A. N. Jones· 2 shared C. T. French· 2 shared H. E. Nunnally· 2 shared K. E. Zarn· 2 shared N. E. Stone· 2 shared S. Knudsen· 2 shared

Activity by Year

2017-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

E. W. Settles

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants

K. E. Zarn, S. A. Jaramillo, A. R. Zapata, N. E. Stone, A. N. Jones, H. E. Nunnally, E. W. Settles, K. Ng, P. S. Keim, S. Knudsen, P. M. Nuijten, A. S. Tijsma, C. T. French

This study shows that stenoparib inhibits SARS-CoV-2 variants in vitro, with EC50 values ranging from 4.1 to 24.1 M, and combination with remdesivir enhances antiviral effects.

bioRxiv · Nov 3, 2021Microbiology

Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression

M. A. Caligiuri, J. Yu, Y. Sun, W. Dong, L. Tian, Y. Rao, C. Qin, S. A. Jaramillo, E. W. Settles, S. Ma, J. Zhang, K. Yu, B. Xu, J. Yan, R. Ma, , P. Feng

This paper develops an oncolytic viral vector-based vaccine that prevents COVID-19 and treats tumor progression in preclinical models.

bioRxiv · Jun 7, 2021 · PreprintMicrobiology

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro.

N. E. Stone, S. A. Jaramillo, A. N. Jones, A. J. Vazquez, M. Martz, L. M. Versluis, M. O. Raniere, H. E. Nunnally, K. E. Zarn, R. Nottingham, J. W. Sahl, D. M. Wagner, S. Knudsen, E. W. Settles, P. S. Keim, C. T. French

This paper evaluates stenoparib, a PARP inhibitor, for antiviral activity against SARS-CoV-2 and other coronaviruses in vitro, showing dose-dependent suppression and potential synergy with remdesivir.

bioRxiv · Nov 12, 2020 · PreprintMicrobiology

Phylogenetic analysis of West Nile Virus in Maricopa County, Arizona: Evidence for dynamic behavior of strains in two major lineages in the American Southwest

C. M. Hepp, J. H. Cocking, M. Valentine, S. J. Young, D. Damian, K. Sheridan, V. Y. Fofanov, J. D. Busch, D. E. Erickson, R. C. Lancione, K. Smith, J. Will, J. Townsend, P. S. Keim, D. M. Engelthaler

The paper analyzes WNV strains in Maricopa County, Arizona, showing two major lineages with dynamic behavior, including local overwintering of NA/WN02 strains.

bioRxiv · Nov 22, 2017Evolutionary Biology